Antiandrogens
Aspirin
Bromhexine
Budesonide
Cannabidiol
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Diet
Ensovibep
Exercise
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Melatonin
Metformin
Molnupiravir
Nigella Sativa
Nitazoxanide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Proxalutamide
Quercetin
Remdesivir
Sleep
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback Home
Home   COVID-19 treatment studies for Favipiravir  COVID-19 treatment studies for Favipiravir  C19 studies: Favipiravir  Favipiravir   Select treatmentSelect treatmentTreatmentsTreatments
Antiandrogens (meta) Lactoferrin (meta)
Aspirin (meta) Melatonin (meta)
Bamlaniv../e.. (meta) Metformin (meta)
Bebtelovimab (meta) Molnupiravir (meta)
Bromhexine (meta) N-acetylcys.. (meta)
Budesonide (meta) Nigella Sativa (meta)
Cannabidiol (meta) Nitazoxanide (meta)
Casirivimab/i.. (meta) Paxlovid (meta)
Colchicine (meta) Peg.. Lambda (meta)
Conv. Plasma (meta) Povidone-Iod.. (meta)
Curcumin (meta) Probiotics (meta)
Diet (meta) Proxalutamide (meta)
Ensitrelvir (meta) Quercetin (meta)
Ensovibep (meta) Remdesivir (meta)
Exercise (meta) Sleep (meta)
Famotidine (meta) Sotrovimab (meta)
Favipiravir (meta) Tixagev../c.. (meta)
Fluvoxamine (meta) Vitamin A (meta)
Hydroxychlor.. (meta) Vitamin C (meta)
Iota-carragee.. (meta) Vitamin D (meta)
Ivermectin (meta) Zinc (meta)

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent: 
0 0.5 1 1.5 2+ Mortality -29% Improvement Relative Risk Ventilation -33% ICU admission -2% Time to resolution of h.. -1% primary Time to hospital discha.. 6% Time to resolution of h.. (b) 17% primary Time to hospital discha.. (b) 32% c19favipiravir.com Shenoy et al. Favipiravir for COVID-19 RCT LATE TREATMENT Favors favipiravir Favors control
Shenoy, 353 patient favipiravir late treatment RCT: 29% higher mortality [p=0.54], 33% higher ventilation [p=0.54], 2% higher ICU admission [p=0.54], and 1% slower recovery [p=0.94] https://c19p.org/shenoy
copied to clipboard
Favipiravir In Adults with Moderate to Severe COVID-19: A Phase 3 Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial
Shenoy et al., medRxiv, doi:10.1101/2021.11.08.21265884 (Preprint)
9 Nov 2021    Source   PDF   Share   Tweet
Late stage RCT with 353 hospitalized patients, showing no significant differences with favipiravir treatment overall, however a trend towards benefit was seen within patients treated relatively early, including a statistically significant shorter time to discharge with treatment.
risk of death, 29.5% higher, RR 1.29, p = 0.54, treatment 14 of 175 (8.0%), control 11 of 178 (6.2%).
risk of mechanical ventilation, 33.0% higher, RR 1.33, p = 0.54, treatment 17 of 175 (9.7%), control 13 of 178 (7.3%).
risk of ICU admission, 1.7% higher, RR 1.02, p = 0.54, treatment 20 of 175 (11.4%), control 20 of 178 (11.2%).
time to resolution of hypoxia, 1.0% higher, HR 1.01, p = 0.94, treatment 157, control 158, primary outcome.
time to hospital discharge, 5.7% lower, HR 0.94, p = 0.60, treatment 175, control 178.
time to resolution of hypoxia, 17.4% lower, HR 0.83, p = 0.29, treatment 157, control 158, earlier treatment subgroup, primary outcome.
time to hospital discharge, 32.0% lower, HR 0.68, p = 0.01, treatment 175, control 178, earlier treatment subgroup.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Shenoy et al., 11/9/2021, Double Blind Randomized Controlled Trial, Kuwait, Middle East, preprint, 8 authors, average treatment delay 6.3 days.
All Studies   Meta Analysis
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are both valuable and complementary. All practical, effective, and safe means should be used. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases mortality, morbidity, collateral damage, and the risk of endemic status. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit